Protalix Operating Margin from 2010 to 2026
| PLX Stock | USD 2.07 0.07 3.50% |
Check Protalix Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protalix Biotherapeutics' main balance sheet or income statement drivers, such as Interest Expense of 1.2 M, Selling General Administrative of 49.3 M or Other Operating Expenses of 32.3 M, as well as many indicators such as Price To Sales Ratio of 2.79, Dividend Yield of 0.0 or PTB Ratio of 3.45. Protalix financial statements analysis is a perfect complement when working with Protalix Biotherapeutics Valuation or Volatility modules.
Protalix | Operating Margin | Build AI portfolio with Protalix Stock |
Latest Protalix Biotherapeutics' Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of Protalix Biotherapeutics over the last few years. It is Protalix Biotherapeutics' Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Protalix Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 0.12 % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
Protalix Operating Margin Regression Statistics
| Arithmetic Mean | (1.23) | |
| Geometric Mean | 0.45 | |
| Coefficient Of Variation | (141.27) | |
| Mean Deviation | 1.40 | |
| Median | (0.35) | |
| Standard Deviation | 1.74 | |
| Sample Variance | 3.02 | |
| Range | 5.5836 | |
| R-Value | 0.55 | |
| Mean Square Error | 2.24 | |
| R-Squared | 0.31 | |
| Significance | 0.02 | |
| Slope | 0.19 | |
| Total Sum of Squares | 48.34 |
Protalix Operating Margin History
About Protalix Biotherapeutics Financial Statements
Protalix Biotherapeutics investors use historical fundamental indicators, such as Protalix Biotherapeutics' Operating Margin, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Protalix Biotherapeutics. Please read more on our technical analysis and fundamental analysis pages.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company was founded in 1993 and is based in Hackensack, New Jersey. Protalix Biotherapeutics operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 202 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Protalix Stock Analysis
When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.